Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 16/20 | 0.45 |
| ▸ | GIPR | P48546 | 9/20 | 0.45 |
| ▸ | GLP1R | P43220 | 3/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2652842 | 0.97 | GCGR (0.42) | GCGRGIPRGLP1RS1PR3S1PR1 | |
| SCHEMBL6752438 | 0.93 | GCGR (0.50) | GCGRGIPRGLP1RS1PR3 | |
| SCHEMBL2652856 | 0.92 | S1PR3 (0.45) | GCGRGIPRS1PR3S1PR1EPHX2 | |
| SCHEMBL7101508 | 0.88 | GCGR (0.45) | GCGRGIPRGLP1REPHX2MCHR1 | |
| SCHEMBL7107328 | 0.85 | GCGR (0.65) | GCGRGIPRGLP1R | |
| SCHEMBL2651118 | 0.84 | GCGR (0.47) | GCGRGIPRGLP1REPHX2 | |
| SCHEMBL2652056 | 0.83 | GCGR (0.53) | GCGRGIPRGLP1R | |
| SCHEMBL2654303 | 0.83 | GCGR (0.41) | GCGRGIPRGLP1REPHX2 | |
| SCHEMBL2652834 | 0.82 | GCGR (0.62) | GCGRGIPRGLP1R | |
| SCHEMBL6754090 | 0.81 | EPHX2 (0.45) | GCGRGIPREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030065031-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-04-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065031-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885GIPR 4/4885GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.